November 24, 2016

Morning Glance
Equity Research Desk
Indices

Value

SENSEX

Pts

Chg (%)

26051.81

91.03

0.35

NIFTY

8033.30

31.00

0.39

SGX NIFTY*

7969.00

(39.50)

(0.49)

DOW Jones

0.31

19083.18

59.31

S&P 500

2204.72

1.78

0.08

Nasdaq

5380.68

(5.67)

(0.11)

FTSE

6817.71

(2.01)

(0.03)

CAC

4529.21

(19.14)

(0.42)

DAX

10662.44

(51.41)

(0.48)

3243.16

2.02

0.06

Nikkei*

18379.50

216.56

1.19

Hang Seng*

22569.00

(107.69)

(0.47)

Shanghai Composite*

*As at 8.30 am
Most Active Call & Put
Symbol

Strike Price

OI

Chg (%)

NIFTY

8100 CE

4930350

8.72

NIFTY

8000 PE

5161275

17.54

Commodity

Value

Pts

Chg (%)

NYMEX Crude (USD)

47.97

0.01

0.02

Brent Crude (USD)

48.93

(0.02)

(0.04)

Gold (INR)

28829.00

(310.00)

(1.06)

Silver (INR)

40526.00

(264.00)

(0.65)

Copper (INR)

395.85

12.65

3.30

ZInc (INR)

184.00

7.10

4.01

19200.00

(30.00)

(0.16)

Cotton (INR)
Currency

Value

USD/Rupee

68.56

0.31

0.45

Euro/Rupee

72.43

(0.15)

(0.21)

Pound/Rupee

85.50

(0.03)

(0.04)

1.05

(0.00)

(0.02)

101.85

0.15

0.15

Euro /USD
Dollar Index

Pts

Value

CBOE VIX

12.43

0.02

0.16

India VIX

18.04

(0.42)

(2.28)

Value

(3)

US 10-Yr Yield

2.35%

BSE

NSE

F&O

2499.34

18594.61

536505.81

Advance (Nos)

1906 (72%)

1189 (76%)

NA

Declines (Nos)

679 (26%)

347 (22%)

NA

51 (2%)

34 (2%)

NA

Unchanged

Top gainer in BSE Sensex were Lupin (5.2%), Asian Paints (3.9%), Tata
Steel (3.8%), NTPC (2.6%) and Larsen (2.2%) whereas top loser in BSE
were M&M (2.0%), HDFC (1.7%), Bharti Airtel (1.2%), HDFC Bank (1.0%)
and Maruti Suzuki (1.0%).
US markets closed largely positive, Dow Jones Industrial Average
closed at 19083, advancing 59 points (0.3%), S&P 500 gained 2 points
(0.1%) to close at 2205 and Nasdaq was down 6 points (0.1%) to close
at 5381.
European markets closed negative, FTSE lost 2 points (0.0%) to close at
6818, CAC was down 19 points (0.4%) to close at 4529 and DAX
declined 51 points (0.5%) to close at 10662.

Macro News

According to a report released by International Data Corp, Cloud

spending in India is likely to grow at CAGR of 26% between FY1520, to reach USD 1.4 bn by 2020. IT spending is likely to grow at
CAGR of 8% during the same period.

The government has allowed NABARD to disburse INR 21000 cr to

cash-starved farmers, helping them sow winter crops like wheat
ahead of the sowing season.

With several states suggesting changes in the model GST and

compensation laws, the GST Council meeting scheduled for
November 25 has been postponed to December 2-3.

Goldman Sachs has forecast a deceleration in Indias GDP growth

to 6.8% in FY17, down from 7.6% last financial year, due to
demonetisation of INR 500 and INR 1000 currency notes.

Government's decision to ban INR 500 and INR 1000 notes have
crippled sales of cars and two-wheelers. The industry is likely to
report fall in volumes for Nov16. According to media reports,
customer footfalls at dealerships are down by over 50% in certain
areas as the sudden cash crunch has led to a virtual withdrawal of
buyers.

Bps change

6.28%

Turnover (INR Crs)

BSE Sensex advanced 91 points or 0.4% to close at 26052. Nifty 50

gained 31 points or 0.4% to settle at 8033. BSE Mid-Cap index was up
145 points or 1.2% to end at 12042. BSE Small-Cap index advanced 179
points or 1.5% to settle at 11806.

Chg (%)

India 10-Yr Yield

Trade Statistics

The market ended on positive note on Wednesday. The market

breadth was positive with 4 gainers for every 3 losers on BSE. 1906
shares advanced whereas 679 shares declined and 51 shares were
unchanged on BSE.

Chg (%)

Volatility

Interest Rates

Pts

Market Summary

November 24, 2016

Morning Glance
Equity Research Desk
Institutional Activity

Key News

Cash
23-Nov

Nov 2016

FIIs (INR Crs)

Buy

4265

77141

Sell

5288

93516

Net

(1023)

(16375)

Buy

2696

53958

Sell

1441

40295

Net

1255

13663

DII (INR Crs)

FII Derivative Statistics (NSE)

Particulars

Buy (INR Crs) Sell (INR Crs)

OI (Nos)

Chg (%)

INDEX FUTURES

6183.55

6238.13

304004

4.92

INDEX OPTIONS

53603.75

54657.34

1321143

0.23

STOCK FUTURES

25490.45

24032.87

982889

2.88

STOCK OPTIONS

4777.75

4816.37

127572

(1.98)

90055.50

89744.71

Total
Gainers & Losers

Price

Chg (%)

Gainers (INR)
Lupin

1487.30

5.22

Asian Paints

942.50

3.87

Tata Steel

392.35

3.80

NTPC

158.25

2.63

Larsen

1357.85

2.16

M&M

1193.25

(2.02)

HDFC

Lupin receives tentative approval for Epzicom tablets

Lupin has received tentative approval for its AbacavirSulfate and
Lamivudine tablets from USFDA to market a generic version of Epzicom
tablets. Epzicom tablets had US sales of USD 426 mn in last 12 months.
Airtel launches Indias first payments bank
Airtel Payments Bank became the first payments bank to start
operations, offering services in Rajasthan in a limited scale. The
payments bank is testing systems and processes ahead of a full scale,
pan-Indian launch. Customers will be offered an interest rate of 7.25%
on deposits in savings account, higher than the 4-6% commercial banks
offers. Airtel Payments Bank is planning to expand its merchant
network in Rajasthan to 100000 by FY17 end.
Reliance Capital sells stakes in radio and TV businesses to Zee Group
Reliance Capital will sell a 49% stake in its radio business and its entire
TV business to Zee Group entities. The transactions will help reduce
Reliance Capitals debt by ~INR 1900 cr. The transactions are expected
to be completed by next year. Reliance capital runs a network of FM
radio channels in India under the brand name of 92.7 Big FM that
reaches out to 45 cities, 1200 towns and over 200 mn people. The TV
broadcasting business currently comprises of two channelsBig Magic
and Big Ganga.

Losers (INR)

1225.95

(1.72)

Bharti Airtel

300.35

(1.22)

HDFC Bank

1184.90

(1.04)

Maruti Suzuki

4881.55

(0.99)

Sectoral Performance

Value

Pts

Chg (%)

S&P BSE Small Cap

11805.55

178.75

1.54

S&P BSE Mid-Cap

12042.45

144.93

1.22

S&P BSE Auto

19650.34

73.29

0.37

S&P BSE BANKEX

21246.51

10.06

0.05

S&P BSE Capital Goods

13669.18

175.06

1.30

7854.83

28.05

0.36

15426.43

330.08

2.19

9319.27

58.17

0.63

S&P BSE Metals

10243.72

232.24

2.32

S&P Oil & Gas

11735.39

18.10

0.15

S&P BSE FMCG

S&P BSE Healthcare
S&P BSE IT

Vietnam bans 39 Indian drug firms for quality standard violations

Vietnam has banned 39 Indian drug firms including Aurobindo Pharma,
Cadila, Mcleods Pharmaceuticals for quality standard violations.
Antibiotics made by Aurobindo and Mcleod and Cadila's anti-rabies
vaccine (Lyssavac) are some of the drugs that are banned.
Key Results today
Jindal Poly, Manpasand, Suven, etc.

International Data
Country

Data

Forecast

Previous

Germany

Final GDP

0.2%

0.2%

Germany

Ifo Business Climate

110.6

110.5

November 24, 2016

Morning Glance
Equity Research Desk
Sharad Avasthi

Head - Equity Research

[email protected]

Tel.: +91-33-4011 4800

Ext.832

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her
compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal r egulations and also legal and statutory requirements of
the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any
recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are
engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE
& MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved
securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are
available on our website i.e. www.spasecurities.com.
SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.
We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock
Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.
General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recip ient and not for circulation. This Report does not constitute a personal
recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed
or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of secu rities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment
/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report sh ould rely on information/data arising out of their own investigations. Readers are advised to seek independent
professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.
This Report has been prepared on the basis of publicly available information, internally developed data and other sources bel ieved by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such
information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.
The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we
would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such
information and opinions are subject to change without notice.
Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and
investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.
This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and
exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the
losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the
NAVs, reduction in the dividend or income, etc.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and
reach different conclusion from the information presented in this report.
SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to
perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.
The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of
India before investing in the Indian Markets.
A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in
the price chart).
Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such
distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is
inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes
without prior written approval of SPA Securities.
List of Associates as per SEBI (Research Analyst) Regulations, 2014
Statements on ownership and material conflicts of interest, compensation - SPA and Associates
Disclosure of interest statement
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month
Immediately preceding the date of the publication of the research report or date of public appearance.
Investment banking relationship with the company covered
Any other material conflict of interest at the time of publishing the research report
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:
Managing/co-managing public offering of securities
Investment banking/merchant banking/brokerage services
products or services other than those above
in connection with research report
Whether Research Analyst has served as an officer, director or employee of the subject company covered
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;
For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

Yes/No
No
No
No
No

No

No
No

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9
For More Information Visit Us At : www.spasecurities.com
SPA Securities Ltd
NSE Cash
NSE Future & Option
NSE Currency Derivatives
BSE Cash
BSE Currency Derivatives
MCX-SX Cash
MCX-SX Future & Option
MCX-SX Currency Derivatives
Mutual Fund
CDSL DP
NSDL DP
SEBI Research Analyst

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-0007
SPA Capital Advisors Limited
SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825
SPA COMTRADE PRIVATE LIMITED
SPA INSURANCE BROKING SERVICES LTD.
Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SEBI Reg. Nos.

INB231178238
INF231173238
INE231178238
INB011178234
INE011178234
INB261178231
INF261178231
INE261178238
ARN 77388
IN-DP-CDSL-485-2008
IN-DP-NSDL-316-2009
INH100002615